Antrodia and Drug Interactions: What to Know

Antrodia Safety

0 drug interaction studies

No systematic study has tested Antrodia camphorata compounds against panels of drugs for interaction potential. The available safety data comes from two small clinical trials and pharmacokinetic profiling in rats.

Qiao et al., J Pharm Biomed Anal, 2015; Tsai et al., BMC CAM, 2016

18 triterpenoids

detected in rat plasma after oral dosing

Platelet risk

potential lowered platelet counts with chemotherapy

CYP1A suppression

shown for mushroom polysaccharides (not Antrodia-specific)

Qiao et al., J Pharm Biomed Anal, 2015; Tsai et al., BMC CAM, 2016

View as image ↗

The honest answer to "does Antrodia camphorata interact with my medications?" is: nobody has systematically checked. No published study has tested Antrodia camphorata extracts or individual antcin compounds against standard panels of drugs for pharmacokinetic or pharmacodynamic interactions. What exists instead is scattered evidence from pharmacokinetic profiling, CYP450 enzyme studies on related mushroom species, and safety data from two small clinical trials where Antrodia was used alongside other medications.

This article compiles that evidence. It does not and cannot provide a definitive drug interaction profile for Antrodia camphorata, because the research to create one has not been done. For the broader safety profile including side effects and toxicology, see Antrodia side effects and safety profile.

What enters the bloodstream: pharmacokinetic profiling

Understanding drug interactions starts with knowing which compounds reach the bloodstream and how long they stay there. Qiao et al. (2015) conducted the most detailed pharmacokinetic study of Antrodia cinnamomea compounds, administering an ethanol extract orally to rats and tracking plasma concentrations over time.^[1]

Eighteen triterpenoids and eight biotransformed metabolites were detected in rat plasma after oral dosing. The absorption and elimination patterns differed by compound class:

• Ergostane triterpenoids (the antcin family) were absorbed and eliminated rapidly, showing fast plasma clearance
• Lanostane triterpenoids (a different structural class) remained in plasma at low concentrations for a relatively long time
• Low-polarity ergostanes underwent hydrogenation or hydroxylation to produce polar metabolites
• High-polarity ergostanes and certain lanostane variants were metabolically stable, meaning they circulated in their original form^[1]

The drug interaction implication is that rapidly cleared compounds (ergostane antcins) have a narrow window during which they could interact with other drugs, while slower-clearing lanostanes have a longer potential interaction window. However, plasma concentration alone does not determine interaction potential. Whether these compounds inhibit or induce the enzymes that metabolize pharmaceutical drugs was not tested in this study.

A separate pharmacokinetic assessment of antroquinonol (a ubiquinone derivative from Antrodia, distinct from antcins) in cancer patients found a mean elimination half-life ranging from 1.30 to 4.33 hours. This relatively short half-life suggests antroquinonol would have limited time-dependent drug interaction potential, but again, no formal interaction testing was performed.

The Qiao et al. data also revealed that biotransformation happens in vivo. Eight metabolites were detected that did not correspond to compounds present in the original extract. These metabolites are formed by liver enzymes acting on absorbed triterpenoids. If those same liver enzymes metabolize pharmaceutical drugs (which is the norm for CYP450 enzymes), competition between antcin metabolism and drug metabolism could alter the clearance rates of either substance. This is the fundamental pharmacokinetic basis for drug interactions with any natural product, and it has not been investigated for Antrodia camphorata.

CYP450 enzymes: the theoretical concern

Most drug interactions occur through cytochrome P450 (CYP450) enzymes, the liver enzymes that metabolize approximately 75% of all pharmaceutical drugs. If a natural product inhibits a CYP450 enzyme, it can increase blood levels of drugs metabolized by that enzyme (potentially causing toxicity). If it induces a CYP450 enzyme, it can decrease drug levels (potentially causing treatment failure).

No study has tested Antrodia camphorata compounds directly against human CYP450 enzymes. However, a study on related mushroom polysaccharides provides indirect evidence of concern.

Hashimoto et al. (2002) found that lentinan (from Lentinus edodes/shiitake) and polysaccharides from Agaricus blazei suppressed both constitutive and 3-methylcholanthrene-induced CYP1A expression and activity in mouse liver when administered intraperitoneally.^[2]

CYP1A enzymes metabolize several drugs including theophylline, caffeine, and certain chemotherapy agents. If Antrodia camphorata polysaccharides produce similar CYP1A suppression (which has not been tested), it could increase blood levels of CYP1A-metabolized drugs.

Critical caveats apply. The Hashimoto study used intraperitoneal injection (bypassing the gut), tested different mushroom species (not Antrodia), and used mice rather than humans. Oral bioavailability of large polysaccharide molecules is generally low, which could limit the clinical relevance of this finding. CYP1A is also not the most pharmacologically important CYP enzyme; CYP3A4, which metabolizes roughly 50% of all drugs, has not been tested against any mushroom polysaccharide in a published study.

The theoretical framework for concern exists, but the Antrodia-specific data does not.

Clinical safety data: what two trials showed

Antrodia combined with chemotherapy

Tsai et al. (2016) conducted a double-blind, randomized controlled trial of Antrodia cinnamomea extract (20 mL twice daily for 30 days) combined with routine chemotherapy in patients with advanced or metastatic adenocarcinoma.^[3]

The primary finding relevant to drug interactions was a potential risk of lowered platelet counts in the Antrodia group. While the study did not find that Antrodia combined with chemotherapy improved outcomes (possibly due to small sample size), the platelet signal raises a specific concern: if Antrodia has antiplatelet activity, combining it with anticoagulants (warfarin, heparin) or antiplatelet drugs (aspirin, clopidogrel) could increase bleeding risk. Combining it with chemotherapy drugs that suppress bone marrow (and therefore platelet production) could compound the thrombocytopenic effect.^[3]

The mechanism of the platelet reduction was not identified. It could be a direct antiplatelet effect of Antrodia compounds, a bone marrow suppressive effect, or a pharmacokinetic interaction where Antrodia increased chemotherapy exposure. Without follow-up mechanistic studies, the cause remains speculative. For more on Antrodia in oncology settings, see Antrodia camphorata safety in oncology patients: Taiwanese clinical data.

Golden-Antrodia camphorata for liver protection

Yen et al. (2022) tested Golden-Antrodia camphorata (300 mg/day containing antroquinonol) vs. placebo for 12 weeks in 80 participants with elevated liver enzymes. No clinically significant safety differences were observed between groups, and biochemical safety parameters showed no treatment-related adverse changes.^[4]

This trial provides modest reassurance about standalone safety at 300 mg/day for 12 weeks, but participants were not taking specific medications of concern, and the study was not designed to detect drug interactions. The absence of adverse safety signals in a 12-week trial does not exclude the possibility of interactions with specific drugs. For the full liver protection data, see Antrodia and alcohol-related liver damage: research review.

Drug classes with theoretical interaction risk

Based on the available evidence, the following drug classes have the most theoretical potential for interaction with Antrodia camphorata, though none has been formally tested:

Anticoagulants and antiplatelet agents. The platelet signal from the Tsai et al. (2016) chemotherapy trial raises concern about additive effects with blood-thinning medications. Warfarin, heparin, clopidogrel, and aspirin all reduce clotting capacity through different mechanisms, and any additional antiplatelet effect from Antrodia could shift bleeding risk.

Chemotherapy drugs metabolized by CYP enzymes. If Antrodia polysaccharides modulate CYP enzyme expression (as shown for related mushroom species), chemotherapy drugs with narrow therapeutic indices could be affected. This is particularly concerning because oncology patients are among the most common users of Antrodia camphorata supplements in Taiwan.

Immunosuppressants. Antrodia camphorata demonstrates immunomodulatory activity in preclinical studies, including enhanced NK cell activity and macrophage activation. If it stimulates immune function, it could theoretically oppose the effects of immunosuppressive drugs used after organ transplantation (tacrolimus, cyclosporine, mycophenolate) or for autoimmune diseases (methotrexate, azathioprine). This is not a hypothetical category of concern: transplant recipients are specifically warned about immune-stimulating supplements because graft rejection can be fatal. No data exists on this interaction, but the theoretical basis is among the strongest of any category listed here.

Antidiabetic medications. Antcin K at 40 mg/kg matched metformin at 300 mg/kg for blood glucose reduction in diabetic mice.^[5] If Antrodia lowers blood glucose in humans through enhanced GLUT4 expression and AMPK phosphorylation (the mechanisms demonstrated in mice), combining it with insulin, sulfonylureas, or other oral hypoglycemics could increase hypoglycemia risk. Hypoglycemia can cause confusion, seizures, and loss of consciousness. No clinical testing of Antrodia combined with antidiabetic drugs has been done.

Hepatotoxic drugs. Antrodia camphorata is promoted for liver protection, and some users may take it specifically to offset the liver toxicity of medications like acetaminophen, statins, or certain antibiotics. Li et al. (2017) showed that antcin B and antcin K reduced NF-kB and inflammatory markers in CCl4-injured mouse livers.^[5] Whether this hepatoprotective effect extends to drug-induced liver injury in humans, or whether Antrodia could mask early warning signs of drug toxicity by suppressing enzyme elevation, has not been studied. The possibility that Antrodia could normalize liver enzyme readings while underlying drug-induced damage continues is a theoretical concern that has received no investigation.

What standardized testing would look like

A proper drug interaction profile for Antrodia camphorata would require:

1. In vitro CYP inhibition/induction screening against major human CYP enzymes (1A2, 2C9, 2C19, 2D6, 3A4) using standardized probe substrates
2. P-glycoprotein transport studies to determine if Antrodia compounds affect drug efflux pumps
3. Protein binding assessment to see if Antrodia compounds displace highly protein-bound drugs
4. Clinical pharmacokinetic studies where Antrodia is co-administered with probe drugs in healthy volunteers

No natural product supplement is required to undergo this testing before sale, so the data gap is unlikely to be filled unless Antrodia compounds enter pharmaceutical drug development. The 90-day oral toxicity study conducted for FDA New Dietary Ingredient (NDI) notification provides basic safety data but does not address drug interactions.

This is not unique to Antrodia. The same data gap exists for the vast majority of herbal supplements and medicinal mushrooms. Even well-studied mushrooms like reishi (Ganoderma lucidum) and turkey tail (Trametes versicolor) lack comprehensive CYP450 interaction profiles. The few exceptions (like St. John's Wort, which was discovered to be a potent CYP3A4 inducer after causing oral contraceptive failures and transplant rejections) illustrate why this testing matters: significant interactions can exist for years before they are identified through adverse event reports rather than proactive screening.

The practical reality is that anyone taking Antrodia camphorata alongside pharmaceutical medications is participating in an unmonitored experiment. The risk may be low for most drug classes, but the data to quantify that risk does not exist.

For guidance on Antrodia dosing in the absence of interaction data, see Antrodia dosage guide: how much to take. For supplement quality concerns, see Antrodia supplement quality: avoiding counterfeits.

The Bottom Line

No systematic drug interaction study exists for Antrodia camphorata. Pharmacokinetic data shows multiple triterpenoids reach the bloodstream after oral dosing. Mushroom polysaccharides from related species suppress CYP1A expression. One clinical trial combining Antrodia with chemotherapy identified a potential platelet-lowering risk. A standalone trial at 300 mg/day showed no safety signals over 12 weeks. The interaction risk with anticoagulants, chemotherapy, immunosuppressants, and antidiabetic drugs is theoretical but untested.

Frequently Asked Questions

Does Antrodia camphorata interact with medications?

No systematic drug interaction study has been published for Antrodia camphorata. One randomized trial combining Antrodia with chemotherapy identified potential platelet-lowering effects (Tsai et al., 2016). A standalone trial at 300 mg/day for 12 weeks showed no safety signals (Yen et al., 2022). The absence of formal interaction testing means interactions cannot be ruled out for any drug class.

Can I take Antrodia with blood thinners?

No published study has tested the combination of Antrodia camphorata with anticoagulant or antiplatelet drugs. A clinical trial combining Antrodia with chemotherapy observed potential platelet count reductions (Tsai et al., 2016), which raises a theoretical concern about additive bleeding risk with warfarin, heparin, aspirin, or clopidogrel. This combination has not been formally evaluated for safety.

Is Antrodia camphorata safe with chemotherapy?

One randomized trial tested Antrodia cinnamomea (20 mL twice daily) alongside chemotherapy in advanced cancer patients for 30 days. The combination did not improve outcomes and identified a potential risk of lowered platelet counts (Tsai et al., 2016). The sample size was small and the mechanism of the platelet signal was not determined. No other clinical trial has examined this combination.

Does Antrodia affect liver enzymes that metabolize drugs?

No study has tested Antrodia camphorata directly against human CYP450 drug-metabolizing enzymes. Polysaccharides from related mushroom species (Lentinus edodes, Agaricus blazei) suppressed CYP1A expression in mice when injected intraperitoneally (Hashimoto et al., 2002). Whether oral Antrodia produces similar effects on CYP enzymes in humans is unknown.

How long do Antrodia compounds stay in the body?

In rats, ergostane triterpenoids (the antcin family) from oral Antrodia extract were absorbed and eliminated rapidly, while lanostane triterpenoids persisted at low plasma concentrations for a longer period (Qiao et al., 2015). Antroquinonol (a different compound class) showed a mean elimination half-life of 1.30 to 4.33 hours in human cancer patients. Human pharmacokinetic data for individual antcin compounds has not been published.

Is Antrodia camphorata safe to take with diabetes medication?

No clinical study has tested Antrodia camphorata alongside insulin or oral antidiabetic drugs. In mice, antcin K at 40 mg/kg matched metformin at 300 mg/kg for blood glucose reduction (Kuo et al., 2016). If Antrodia lowers blood glucose in humans, combining it with diabetes medication could theoretically increase hypoglycemia risk. This interaction has not been tested.

Sources & References

1. 1RTHM-00398·Qiao, Xue et al. (2015). “Metabolites identification and multi-component pharmacokinetics of ergostane and lanostane triterpenoids in the anticancer mushroom Antrodia cinnamomea..” Journal of pharmaceutical and biomedical analysis.Study breakdown →PubMed →↩
2. 2RTHM-00047·Hashimoto, Takashi et al. (2002). “Suppressive effect of polysaccharides from the edible and medicinal mushrooms, Lentinus edodes and Agaricus blazei, on the expression of cytochrome P450s in mice..” Bioscience.Study breakdown →PubMed →↩
3. 3RTHM-00453·Tsai, Ming-Yen et al. (2016). “A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer..” BMC complementary and alternative medicine.Study breakdown →PubMed →↩
4. 4RTHM-00805·Yen, Yu-Ting et al. (2022). “Clinical Benefits of Golden-Antrodia Camphorata Containing Antroquinonol in Liver Protection and Liver Fat Reduction After Alcoholic Hepatitis..” Frontiers in pharmacology.Study breakdown →PubMed →↩
5. 5RTHM-00479·Li, Zi-Wei et al. (2017). “Hepatoprotective activities of Antrodia camphorata and its triterpenoid compounds against CCl4-induced liver injury in mice..” Journal of ethnopharmacology.Study breakdown →PubMed →↩